Methylphenidate for treating tobacco dependence in non-attention deficit hyperactivity disorder smokers: a pilot randomized placebo-controlled trial

Richard D Hurt, Jon O Ebbert, Ivana T Croghan, Darrell R Schroeder, Amit Sood, J Taylor Hays, Richard D Hurt, Jon O Ebbert, Ivana T Croghan, Darrell R Schroeder, Amit Sood, J Taylor Hays

Abstract

Background: Methylphenidate blocks the re-uptake of dopamine by binding to the dopamine transporter in the presynaptic cell membrane and increases extracellular dopamine levels. Similarities in neuropsychologic effects between nicotine and methylphenidate make it an intriguing potential therapeutic option. Previous research of methylphenidate in smokers has suggested a possible beneficial effect for the relief of nicotine withdrawal symptoms, but showed no efficacy in helping smokers with attention deficit hyperactivity disorder (ADHD) to stop smoking.

Methods: To investigate potential efficacy for relieving nicotine withdrawal symptoms and promoting smoking abstinence, we conducted a randomized, double-blind, placebo-controlled, phase II study of once-a-day osmotic-release oral system methylphenidate (OROS-MPH, Concerta®) at a target dose of 54-mg/day for 8 weeks compared with placebo in 80 adult cigarette smokers.

Results: Of the 80 randomized subjects and median smoking rate was 20 cigarettes per day. At the end of the medication phase, the biochemically confirmed 7-day point prevalence smoking abstinence was 10% (4/40) for the placebo group and 2.5% (1/40) for the OROS-MPH group. Nicotine withdrawal was not found to differ significantly between treatment groups during the first 14 days following the start of medication prior to the target quit date (p = 0.464) or during the first 14 days following the target quit date (p = 0.786).

Conclusion: We observed no evidence of efficacy of OROS-MPH to aid smokers to stop smoking. Although there are biologically plausible hypotheses that support the use of OROS-MPH for treating tobacco dependence, we found no evidence to support such hypotheses. In addition to no increase in smoking abstinence, we saw no effect of OROS-MPH for tobacco withdrawal symptom relief and no change in smoking rates was observed in the OROS-MPH group compared to the placebo group.

Figures

Figure 1
Figure 1
Composite nicotine withdrawal scones before and after the target quit date.

References

    1. Sharma A, Brody AL. In vivo brain imaging of human exposure to nicotine and tobacco. Handb Exp Pharmacol. 2009;192:145–171. full_text.
    1. Hurd YL, Ungerstedt U. In vivo neurochemical profile of dopamine uptake inhibitors and releasers in rat caudate-putamen. Eur J Pharmacol. 1989;166(2):251260.
    1. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, Hitzemann R, Pappas N. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry. 1998;155(10):1325–1331.
    1. Robinson MD, Anastasio GD, Little JM, Sigmon JL Jr, Menscer D, Pettice YJ, Norton HJ. Ritalin for nicotine withdrawal: Nesbitt's paradox revisited. Addict Behav. 1995;20(4):481–490. doi: 10.1016/0306-4603(95)00009-2.
    1. Rush CR, Higgins ST, Vansickel AR, Stoops WW, Lile JA, Glaser PE. Methylphenidate increases cigarette smoking. Psychopharmacology (Berl) 2005;181(4):781–789. doi: 10.1007/s00213-005-0021-8.
    1. Vansickel AR, Stoops WW, Glaser PE, Rush CR. A pharmacological analysis of stimulant-induced increases in smoking. Psychopharmacology (Berl) 2007;193(3):305–313. doi: 10.1007/s00213-007-0786-z.
    1. Winhusen TM, Somoza EC, Brigham GS, Liu DS, Green CA, Covey LS, Croghan IT, Adler LA, Weiss RD, Leimberger JD, Lewis DF, Dorer EM. Impact of attentiondeficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2010. in press .
    1. Fagerstrom K, Furberg H. A comparison of the Fagerstrom Test for Nicotine Dependence and smoking prevalence across countries. Addiction. 2008;103(5):841845. doi: 10.1111/j.1360-0443.2008.02190.x.
    1. Buchsbaum DG, Buchanan RG, Centor RM, Schnoll SH, Lawton MJ. Screening for alcohol abuse using CAGE scores and likelihood ratios. Ann Intern Med. 1991;115(10):774–777.
    1. Skinner D. In: Encyclopedia of drugs, alcohol, and addictive behaviors. 2. Carson-DeWitt R, editor. Durham, NC: Macmillan Reference; 2001. Assessment of substance abuse: Drug abuse screening test (DAST)
    1. Biener L, Abrams DB. The Contemplation Ladder: validation of a measure of readiness to consider smoking cessation. Health Psychol. 1991;10(5):360–365. doi: 10.1037/0278-6133.10.5.360.
    1. Radloff S. The CES-D scale: a self-report depression scale for research in the general population. 1977. pp. 385–401.
    1. Hughes JR, Hatsukami DK. Errors in using tobacco withdrawl scale. Tob Control. 1998. pp. 92–93.
    1. Sood A, Ebbert JO, Prasad K, Croghan IT, Bauer B, Schroeder DR. A randomized clinical trial of St. John's wort for smoking cessation. J Altern Complement Med. pp. 761–767.
    1. Sood A, Ebbert JO, Wyatt KD, Croghan IT, Schroeder DR, Sood R, Hays JT. Gabapentin for smoking cessation. Nicotine Tob Res. pp. 300–304.
    1. Warner KE, Burns DM. Hardening and the hard-core smoker: concepts, evidence, and implications. Nicotine Tob Res. 2003;5(1):37–48. doi: 10.1080/1462220021000060428.
    1. Tashkin DP, Rennard SI, Martin P, Ramachandran S, Martin UJ, Silkoff PE, Goldman M. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs. 2008;68(14):1975–2000. doi: 10.2165/00003495-200868140-00004.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit